TY - JOUR
T1 - Development and Characterization of a Collagen-Based Three-Dimensional In Vitro Model to Mimic Biofilm Formation in a Wound Bed
AU - Zuniga, Kameel
AU - Thompson, Marc
AU - Muire, Preeti J.
AU - Clay, Nicholas
AU - Karna, S. L.Rajasekhar
AU - Leatherman, Logan
AU - Lopez, Rebecca
AU - You, Tao
AU - Harm, Krystle
AU - Brammer, Jerod
AU - Wenke, Joseph
AU - Christy, Robert
AU - Kowalczewski, Christine
N1 - Publisher Copyright:
© 2025 American Chemical Society.
PY - 2025
Y1 - 2025
N2 - Current studies using in vitro biofilm culturing systems have been instrumental at elucidating wound biofilm formation but fail to account for the diverse environment that bacteria are exposed to within the host. In the current study, we recapitulated this wound biofilm microenvironment by creating a hydrogel composed of collagen, thrombin, fibrinogen, meat broth, and FBS and subsequently infected the scaffolds with UAMS-1. We characterized the material properties of the hydrogel (noninfected) and found no significant differences in the storage modulus when fibrin was added to the collagen hydrogel. When infected with UAMS-1, temporal growth and polysaccharide formation were observed through plating, SEM, and histological staining, indicative of biofilm formation. PCR analysis revealed heightened expression of adhesion-associated genes with no increase in expression of metabolic genes, indicating significant increase in the formation of a robust biofilm over time. Vancomycin was ineffective in eradicating the already-developed biofilm, whereas the total CFUs in rifampin-treated models decreased significantly compared to those in the untreated group. Although it was not significant, an increase in SCVs was observed in the rifampin-treated group, suggesting that rifampin may create a harsher environment against the Staphylococcus aureus, allowing the increase in more resistant bacteria. The persistence of an infection in our rifampin-treated 3D in vitro wound model indicates an increased similarity to the host environment compared to that of a static biofilm model.
AB - Current studies using in vitro biofilm culturing systems have been instrumental at elucidating wound biofilm formation but fail to account for the diverse environment that bacteria are exposed to within the host. In the current study, we recapitulated this wound biofilm microenvironment by creating a hydrogel composed of collagen, thrombin, fibrinogen, meat broth, and FBS and subsequently infected the scaffolds with UAMS-1. We characterized the material properties of the hydrogel (noninfected) and found no significant differences in the storage modulus when fibrin was added to the collagen hydrogel. When infected with UAMS-1, temporal growth and polysaccharide formation were observed through plating, SEM, and histological staining, indicative of biofilm formation. PCR analysis revealed heightened expression of adhesion-associated genes with no increase in expression of metabolic genes, indicating significant increase in the formation of a robust biofilm over time. Vancomycin was ineffective in eradicating the already-developed biofilm, whereas the total CFUs in rifampin-treated models decreased significantly compared to those in the untreated group. Although it was not significant, an increase in SCVs was observed in the rifampin-treated group, suggesting that rifampin may create a harsher environment against the Staphylococcus aureus, allowing the increase in more resistant bacteria. The persistence of an infection in our rifampin-treated 3D in vitro wound model indicates an increased similarity to the host environment compared to that of a static biofilm model.
KW - 3D model
KW - biofilm
KW - collagen
KW - fibrinogen
KW - small colony variants
KW - Staphylococcus aureus
KW - thrombin
KW - wound
UR - http://www.scopus.com/inward/record.url?scp=105006711555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105006711555&partnerID=8YFLogxK
U2 - 10.1021/acsabm.5c00100
DO - 10.1021/acsabm.5c00100
M3 - Article
C2 - 40433975
AN - SCOPUS:105006711555
SN - 2576-6422
JO - ACS Applied Bio Materials
JF - ACS Applied Bio Materials
ER -